[go: up one dir, main page]

WO2006020145A3 - Inhibiteurs de flt3 a des fins d'immunodepression - Google Patents

Inhibiteurs de flt3 a des fins d'immunodepression Download PDF

Info

Publication number
WO2006020145A3
WO2006020145A3 PCT/US2005/025318 US2005025318W WO2006020145A3 WO 2006020145 A3 WO2006020145 A3 WO 2006020145A3 US 2005025318 W US2005025318 W US 2005025318W WO 2006020145 A3 WO2006020145 A3 WO 2006020145A3
Authority
WO
WIPO (PCT)
Prior art keywords
immune
flt3
disease
subject
immune suppression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/025318
Other languages
English (en)
Other versions
WO2006020145A2 (fr
Inventor
Donald Small
Katherine A Whartenby
Drew Pardoll
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Priority to JP2007522605A priority Critical patent/JP5704785B2/ja
Priority to ES05790718.0T priority patent/ES2464281T3/es
Priority to AU2005274852A priority patent/AU2005274852B2/en
Priority to CA2574150A priority patent/CA2574150C/fr
Priority to EP05790718.0A priority patent/EP1778224B1/fr
Priority to US11/632,924 priority patent/US20090054358A1/en
Publication of WO2006020145A2 publication Critical patent/WO2006020145A2/fr
Anticipated expiration legal-status Critical
Publication of WO2006020145A3 publication Critical patent/WO2006020145A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne de nouvelles techniques permettant de déprimer le système immunitaire et de traiter des troubles associés à l'immunité. Des thérapies de cette invention consistent à administrer un composé inhibiteur de FLT3 à un sujet nécessitant un traitement, tel qu'un sujet souffrant d'un rejet d'organe, d'un rejet de transplantation de moelle épinière, d'un syndrome de déficience immune acquise, d'arthrite, d'anémie aplasique, d'une maladie hôte dirigée contre le greffon, de la maladie de Graves, d'encéphalitomyélite allergique expérimentale établie, de sclérose en plaques, du lupus ou d'un trouble neurologique. Cette invention concerne aussi des techniques de recherche d'agents thérapeutiques qui permettant de traiter des troubles immunitaires, comprenant l'utilisation d'une souris possédant un niveau élevé d'activité du récepteur FLT3.
PCT/US2005/025318 2004-07-19 2005-07-14 Inhibiteurs de flt3 a des fins d'immunodepression Ceased WO2006020145A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2007522605A JP5704785B2 (ja) 2004-07-19 2005-07-14 免疫抑制のためのｆｌｔ３阻害剤
ES05790718.0T ES2464281T3 (es) 2004-07-19 2005-07-14 Inhibidores de FLT3 para la inmunosupresión
AU2005274852A AU2005274852B2 (en) 2004-07-19 2005-07-14 FLT3 inhibitors for immune suppression
CA2574150A CA2574150C (fr) 2004-07-19 2005-07-14 Inhibiteurs de flt3 a des fins d'immunodepression
EP05790718.0A EP1778224B1 (fr) 2004-07-19 2005-07-14 Inhibiteurs de flt3 a des fins d'immunodepression
US11/632,924 US20090054358A1 (en) 2004-07-19 2005-07-14 Flt3 inhibitors for immune suppression

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58951104P 2004-07-19 2004-07-19
US60/589,511 2004-07-19

Publications (2)

Publication Number Publication Date
WO2006020145A2 WO2006020145A2 (fr) 2006-02-23
WO2006020145A3 true WO2006020145A3 (fr) 2007-03-08

Family

ID=35907955

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/025318 Ceased WO2006020145A2 (fr) 2004-07-19 2005-07-14 Inhibiteurs de flt3 a des fins d'immunodepression

Country Status (8)

Country Link
US (1) US20090054358A1 (fr)
EP (1) EP1778224B1 (fr)
JP (1) JP5704785B2 (fr)
CN (2) CN103251953A (fr)
AU (1) AU2005274852B2 (fr)
CA (1) CA2574150C (fr)
ES (1) ES2464281T3 (fr)
WO (1) WO2006020145A2 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101489562B (zh) * 2006-07-21 2012-04-18 赛福伦公司 用于治疗脊髓增生病的jak抑制剂
US8969347B2 (en) 2008-06-03 2015-03-03 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US9359379B2 (en) 2012-10-02 2016-06-07 Intermune, Inc. Anti-fibrotic pyridinones
US9498476B2 (en) 2008-06-04 2016-11-22 Albany Molecular Research, Inc. Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
US9499531B2 (en) 2004-07-15 2016-11-22 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US9527816B2 (en) 2005-05-10 2016-12-27 Intermune, Inc. Method of modulating stress-activated protein kinase system

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1991547A2 (fr) * 2006-03-09 2008-11-19 Pharmacopeia, Inc. Inhibiteurs de la 8-hétéroarylpurine mnk2 pour le traitement de troubles métaboliques
WO2008031835A2 (fr) * 2006-09-13 2008-03-20 Novartis Ag Méthode de traitement de maladies auto-immunes à l'aide d'inhibiteurs de la voie vegf
WO2009030270A1 (fr) * 2007-09-03 2009-03-12 Novartis Ag Dérivés dhydroindoles utilisés pour traiter la maladie de parkinson
WO2010093808A1 (fr) * 2009-02-11 2010-08-19 Reaction Biology Corp. Inhibiteurs de kinase sélectifs
CA2760837C (fr) 2009-05-12 2018-04-03 Albany Molecular Research, Inc. 7-([1,2,4]triazolo[1,5-.alpha.]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline et son utilisation
KR20120034644A (ko) 2009-05-12 2012-04-12 알바니 몰레큘라 리써치, 인크. 아릴, 헤테로아릴, 및 헤테로사이클 치환된 테트라하이드로이소퀴놀린 및 이의 용도
WO2010132487A1 (fr) 2009-05-12 2010-11-18 Bristol-Myers Squibb Company Formes cristallines de (s)-7-([1,2,4]triazolo[1,5-a] pyridin -6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline et leurs utilisations
WO2011106168A1 (fr) 2010-02-24 2011-09-01 Dcam Pharma Inc Composés de purine pour le traitement de maladies auto-immunes et démyélinisantes
JP5835729B2 (ja) * 2010-09-02 2015-12-24 国立大学法人京都大学 筋萎縮性側索硬化症の予防および治療用医薬組成物
AU2012367141B2 (en) 2012-01-28 2016-12-22 Merck Patent Gmbh Triazolo[4,5-d]pyrimidine derivatives
US20150051202A1 (en) 2012-03-07 2015-02-19 Merck Patent Gmbh Triazolopyrazine derivatives
CN102648906A (zh) * 2012-05-17 2012-08-29 大连理工大学 舒尼替尼在制备乙酰胆碱酯酶抑制剂中的应用
CN103788066A (zh) * 2012-10-31 2014-05-14 韩冰 一类保护移植器官的化合物及其用途
US9617266B2 (en) 2013-03-05 2017-04-11 Merck Patent Gmbh Imidazopyrimidine derivatives
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
CN105829885B (zh) 2013-10-17 2020-08-18 综合医院公司 鉴定响应于用于自身免疫性疾病的治疗的受试者的方法以及用于治疗该疾病的组合物
NO2699580T3 (fr) 2014-01-24 2018-02-24
JP6525437B2 (ja) 2014-04-02 2019-06-05 インターミューン， インコーポレイテッド 抗線維性ピリジノン
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
US11029317B2 (en) * 2014-09-18 2021-06-08 The Johns Hopkins University Compositions and methods for detecting anti-endothelial cell antibodies in allograft rejection
WO2017059132A1 (fr) * 2015-09-29 2017-04-06 The General Hospital Corporation Méthodes de traitement et de diagnostic d'une maladie à l'aide de biomarqueurs pour thérapie par bcg
CN108472298B (zh) 2015-11-24 2021-04-20 深圳阿拉丁医疗科技有限公司 选择性激酶抑制剂
IL303455A (en) 2016-06-17 2023-08-01 Crispr Therapeutics Ag Compositions and methods for the depletion of cd117+cells
EP3559006A4 (fr) * 2016-12-23 2021-03-03 Arvinas Operations, Inc. Composés et procédés pour la dégradation ciblée de polypeptides de kinase du foie f tal
JP7256744B2 (ja) 2017-01-20 2023-04-12 マジェンタ セラピューティクス インコーポレイテッド Ｃｄ１３７＋細胞の枯渇のための組成物および方法
WO2018217766A1 (fr) 2017-05-22 2018-11-29 Whitehead Institute For Biomedical Research Composés d'amélioration de l'expression de kcc2 et leurs utilisations
CA3006798A1 (fr) 2017-06-02 2018-12-02 Pfizer Inc. Anticorps specifiques a la flt3 et leurs utilisations
MX2020008479A (es) 2018-02-14 2020-11-24 Viela Bio Inc Anticuerpos frente al ligando del receptor de tirosina cinasa 3 similar al sarcoma de mcdonough felino (fms) (flt3l) y tratamiento de enfermedades autoinmunes e inflamatorias.
EP3758708B1 (fr) 2018-03-01 2024-11-27 AstraZeneca AB Compositions pharmaceutiques comprenant du (2s)-{(1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide
CN109001177A (zh) * 2018-06-14 2018-12-14 福建师范大学 一种尿液中酪氨酸的检测方法
US11998553B2 (en) 2018-07-17 2024-06-04 Insmed Incorporated Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis
CN110833554B (zh) * 2018-08-15 2022-03-08 广西梧州制药（集团）股份有限公司 吡唑并嘧啶衍生物在治疗自身免疫性甲状腺疾病的用途
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021138391A1 (fr) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Composés d'indazole
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
EP4509125A1 (fr) * 2022-04-12 2025-02-19 Hefei Youyuan Pharmaceutical Co., Ltd. Nouvelle utilisation d'un composé pyrazolopyrimidine
WO2024148308A1 (fr) 2023-01-06 2024-07-11 Insmed Incorporated Nouveaux inhibiteurs de dpp1 réversibles et leurs utilisations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020160974A1 (en) * 2001-01-09 2002-10-31 Banchereau Jacques F. Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
US20030219827A1 (en) * 2002-02-20 2003-11-27 Comb Michael J. Phospho-specific antibodies to Flt3 and uses thereof
WO2004037784A2 (fr) * 2002-10-21 2004-05-06 Irm Llc Pyrrolidones ayant une activité anti-vih

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993007153A1 (fr) * 1991-10-10 1993-04-15 Schering Corporation Derives de staurosporine 4'-(n-substituee-n-oxydee)
US5461146A (en) * 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
EP1330444B1 (fr) * 2000-11-01 2011-03-23 Millennium Pharmaceuticals, Inc. Composes heterocycliques azotes et leur procede de fabrication
JP2002275068A (ja) * 2001-03-16 2002-09-25 Kyowa Hakko Kogyo Co Ltd アポトーシス誘導剤
US20040213786A1 (en) * 2001-08-24 2004-10-28 Rappaport Family Institute For Research In The Medical Sciences Compositions and methods for treating T-cell mediated autoimmune diseases
TWI302836B (en) * 2001-10-30 2008-11-11 Novartis Ag Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
EP1581526B1 (fr) * 2002-12-18 2009-03-11 Vertex Pharmaceuticals Incorporated Derives de benzisoxazole utiles en tant qu'inhibiteurs des proteines kinases
TWI324604B (en) * 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020160974A1 (en) * 2001-01-09 2002-10-31 Banchereau Jacques F. Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
US20030219827A1 (en) * 2002-02-20 2003-11-27 Comb Michael J. Phospho-specific antibodies to Flt3 and uses thereof
WO2004037784A2 (fr) * 2002-10-21 2004-05-06 Irm Llc Pyrrolidones ayant une activité anti-vih

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GRISWOLD ET AL.: "Effects of MLN518, a Dual FLT3 and KIT inhibitor, on Normal and Malignant Hematopoiesis", BLOOD, vol. 104, no. 9, 1 November 2004 (2004-11-01), pages 2912 - 2918, XP003008810 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9499531B2 (en) 2004-07-15 2016-11-22 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US9527816B2 (en) 2005-05-10 2016-12-27 Intermune, Inc. Method of modulating stress-activated protein kinase system
CN101489562B (zh) * 2006-07-21 2012-04-18 赛福伦公司 用于治疗脊髓增生病的jak抑制剂
US8969347B2 (en) 2008-06-03 2015-03-03 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US9290450B2 (en) 2008-06-03 2016-03-22 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US9498476B2 (en) 2008-06-04 2016-11-22 Albany Molecular Research, Inc. Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
US9359379B2 (en) 2012-10-02 2016-06-07 Intermune, Inc. Anti-fibrotic pyridinones

Also Published As

Publication number Publication date
EP1778224B1 (fr) 2014-03-26
CA2574150C (fr) 2018-02-27
AU2005274852A1 (en) 2006-02-23
EP1778224A2 (fr) 2007-05-02
ES2464281T3 (es) 2014-06-02
CA2574150A1 (fr) 2006-02-23
JP2008506778A (ja) 2008-03-06
JP5704785B2 (ja) 2015-04-22
EP1778224A4 (fr) 2010-10-20
AU2005274852B2 (en) 2011-12-08
WO2006020145A2 (fr) 2006-02-23
CN103251953A (zh) 2013-08-21
CN101022799A (zh) 2007-08-22
US20090054358A1 (en) 2009-02-26

Similar Documents

Publication Publication Date Title
WO2006020145A3 (fr) Inhibiteurs de flt3 a des fins d'immunodepression
WO2006047516A3 (fr) Composes et compositions servant d'inhibiteurs d'activite de recepteur cannabinoide de type 1
EP2116245A3 (fr) combinaisons d'inhibiteurs de la kinase EGFR pour le traitement de désordres respiratoires et de l'appareil digestif
WO2006002177A3 (fr) Anticorps anti-recepteur aux interferons alpha 1 et leurs utilisations
WO2003002596A3 (fr) Nouvelle utilisation d'inhibiteurs de la dipeptidyl peptidase iv
WO2005059106A3 (fr) Anticorps contre l'interferon alpha et leur utilisations
TW200633980A (en) Pyridones useful as inhibitors of kinases
MA30318B1 (fr) Composes de sulfonamide de pyrimidinyle inhibant l'adhesion leucocytaire mediee par vla-4
WO2006037106A3 (fr) Systemes bases sur cai et methodes de traitement localise de maladies oculaires et autres
WO2005028475A3 (fr) Compositions utiles pour inhiber des proteines kinases
WO2007126934A3 (fr) Antagonistes des récepteurs de l'orexine sous forme de composés amidoéthylthioéther
WO2008008551A3 (fr) Prolines bis-amides substituées en 2 antagonistes du récepteur de l'oréxine
TW200607803A (en) Pyrrole inhibitors of erk protein kinase, synthesis thereof and intermediates thereto
WO2005063766A3 (fr) Inhibiteurs heterocycliques bicycliques des kinases p-38
WO2004058769A3 (fr) Compositions utiles en tant qu'inhibiteurs des proteine kinases
ZA200704476B (en) Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases
ZA200710379B (en) Pyrrolopyridines useful as inhibitors of protein kinase
TW200621736A (en) Mitotic kinesin inhibitors and methods of use thereof
NO20070347L (no) Modulatorer av alfa7 nikotinske acetylkolinreseptorer og terapeutiske anvendelser
WO2008049842A3 (fr) Nouvelles compositions pharmaceutiques pour le traitement de troubles respiratoires et gastro-intestinaux
WO2007087151A3 (fr) Méthode de traitement d'un dysfonctionnement cognitif
WO2006060127A3 (fr) Composes a activite a la fois inhibitrice de la pde et antagoniste ou agoniste partielle des recepteurs $g(b)-adrenergiques pour le traitement de l'insuffisance cardiaque
ZA200800992B (en) Benzimidazoles useful as inhibitors of protein kinases
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
IL171384A (en) Use of slurp-1 in the preparation of medicaments for the treatment of neurological disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2574150

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007522605

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005790718

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 583/KOLNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2005274852

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2005274852

Country of ref document: AU

Date of ref document: 20050714

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005274852

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200580031410.1

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005790718

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11632924

Country of ref document: US